港股异动 | 来凯医药-B(02105)现涨超15% 礼来持续加码ActRII靶点 LAE102美国1期启动在即

智通财经2025-04-22

智通财经APP获悉，来凯医药-B(02105)现涨超15%，截至发稿，涨13.09%，报12.96港元，成交额1277.08万港元。消息面上，2025年4月，一则来自全球临床试验注册平台ClinicalTrials网站的信息显示，来凯医药更新了其自研管线LAE102针对肥胖症在美国的一项I期临床试验(NCT06908707)的相关信息。一个引人注意的变化是：修订后的临床方案，出现了合作伙伴礼来的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2529360047?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-22 10:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2529360047","market":"us","top_or_hot":-1,"title":"港股异动 | 来凯医药-B(02105)现涨超15% 礼来持续加码ActRII靶点 LAE102美国1期启动在即","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，来凯医药-B(02105)现涨超15%，截至发稿，涨13.09%，报12.96港元，成交额1277.08万港元。消息面上，2025年4月，一则来自全球临床试验注册平台ClinicalTrials网站的信息显示，来凯医药更新了其自研管线LAE102针对肥胖症在美国的一项I期临床试验(NCT06908707)的相关信息。一个引人注意的变化是：修订后的临床方案，出现了合作伙伴礼来的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1282052.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 来凯医药-B(02105)现涨超15% 礼来持续加码ActRII靶点 LAE102美国1期启动在即</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 来凯医药-B(02105)现涨超15% 礼来持续加码ActRII靶点 LAE102美国1期启动在即\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-22 10:09 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1282052.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，来凯医药-B(02105)现涨超15%，截至发稿，涨13.09%，报12.96港元，成交额1277.08万港元。消息面上，2025年4月，一则来自全球临床试验注册平台ClinicalTrials网站的信息显示，来凯医药更新了其自研管线LAE102针对肥胖症在美国的一项I期临床试验(NCT06908707)的相关信息。一个引人注意的变化是：修订后的临床方案，出现了合作伙伴礼来的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1282052.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2750360641.GBP","symbol_name":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1282052.html","article_id":"2529360047","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2529360047","pubTimestamp":1745287788,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，来凯医药-B现涨超15%，截至发稿，涨13.09%，报12.96港元，成交额1277.08万港元。消息面上，2025年4月，一则来自全球临床试验注册平台ClinicalTrials网站的信息显示，来凯医药更新了其自研管线LAE102针对肥胖症在美国的一项I期临床试验的相关信息。同时，来自ClinicalTrials网站的信息也显示，该研究计划于2025年4月底启动临床入组，预计在2025年8月结束。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU2063271972.USD":"富兰克林创新领域基金","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0385154629.USD":"贝莱德营养科学基金A2","02105":"来凯医药-B","BK4588":"碎股","LU1548497426.USD":"安联环球人工智能AT Acc","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1232071149.USD":"AZ FUND 1 GLOBAL GROWTH SELECTOR \"AAZ\" (USDHDG) ACC","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","BK4534":"瑞士信贷持仓"},"translate_title":"Changes in Hong Kong stocks Laikai Pharmaceutical-B (02105) is now up more than 15% Eli Lilly continues to increase its ActRII target LAE102 US phase 1 is about to launch","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02105":1},"content_text":"智通财经APP获悉，来凯医药-B(02105)现涨超15%，截至发稿，涨13.09%，报12.96港元，成交额1277.08万港元。消息面上，2025年4月，一则来自全球临床试验注册平台ClinicalTrials网站的信息显示，来凯医药更新了其自研管线LAE102针对肥胖症在美国的一项I期临床试验(NCT06908707)的相关信息。一个引人注意的变化是：修订后的临床方案，出现了合作伙伴礼来的名字。同时，来自ClinicalTrials网站的信息也显示，该研究计划于2025年4月底启动临床入组，预计在2025年8月结束。财通证券发布研报称，阻断激活素受体(ActR)通路被临床用于治疗肌肉萎缩相关疾病(如SMA等遗传性神经肌肉疾病或因癌症、减肥导致的肌肉流失)。近年来GLP1RA类药物的广泛使用，目前的GLP-1RA疗法会带来使用者约25-40%肌肉流失，因此老龄人群和减重人群也存在较大的增肌治疗需求。建议关注国内布局相关资产的公司，如来凯医药等。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2529360047","isCrawlerRequest":true}